Core Insights - The report highlights significant target price increases for several companies, with 百利天恒 leading at 375.97%, followed by 泽璟制药 at 88.56% and 长城汽车 at 83.66% [1][2]. Target Price Increases - 百利天恒 (CITIC Securities) has a target price increase of 375.97%, with a latest price of 1322.00 CNY [2]. - 泽璟制药 (Huatai Securities) shows a target price increase of 88.56%, with a latest price of 166.16 CNY [2]. - 长城汽车 (CITIC Securities) has a target price increase of 83.66%, with a latest price of 38.00 CNY [2]. - Other notable increases include 工业富联 (Huatai Securities) at 73.31% and 宁德时代 (Dongwu Securities) at 71.71% [2]. Broker Recommendations - A total of 265 companies received broker recommendations from January 26 to February 1, with 青岛银行 receiving the highest number at 8 recommendations [3]. - 先导智能 and 万辰集团 each received 5 recommendations [3]. Rating Adjustments - During the same period, 8 companies had their ratings upgraded, including 上海家化 (Guolian Minsheng Securities) from "Hold" to "Recommend" [4]. - 中兴通讯 (Dongguan Securities) was upgraded from "Cautious Recommend" to "Buy" [4]. - 特变电工 (Huatai Securities) was upgraded from "Hold" to "Buy" [4]. Rating Downgrades - Two companies had their ratings downgraded, including 金辰股份 (Zheshang Securities) from "Buy" to "Hold" [5]. - 华设集团 (Guotai Junan Securities) was downgraded from "Buy" to "Hold" [5]. First Coverage - A total of 75 instances of first coverage were reported, with 陕西旅游 receiving a "Outperform Industry" rating from China International Capital Corporation [6]. - 柏楚电子 was rated "Hold" by Guotai Junan Securities, and 博汇纸业 received a "Buy" rating from Guohai Securities [6].

Performance Highlights - New Yi Sheng (300502.SZ) expects net profit between 9.4 billion and 9.9 billion CNY, a year-on-year increase of 231.24% to 248.86% due to rising demand for high-speed optical modules driven by global computing power investments[4] - Han's Chip (688256.SH) anticipates net profit between 1.85 billion and 2.15 billion CNY, turning from a loss of 450 million CNY last year, benefiting from the growing demand for AI computing power[5] - Zhongji Xuchuang (300308.SZ) projects net profit between 9.8 billion and 11.8 billion CNY, a year-on-year growth of 89.50% to 128.17%, driven by strong customer investment in computing infrastructure[6] - Runze Technology (300442.SZ) expects net profit between 5 billion and 5.3 billion CNY, a year-on-year increase of 179.28% to 196.03%, largely due to non-recurring gains from public REITs issuance[10] Underperformance Highlights - Great Wall Motors (601633.SH) forecasts net profit of 9.912 billion CNY, a year-on-year decline of 21.71% due to increased marketing expenses and competitive pressures[36] - GAC Group (601238.SH) expects a net loss between 8 billion and 9 billion CNY, turning from a profit of 824 million CNY last year, impacted by fierce competition and increased asset impairment provisions[39] - Xiexin Integrated (002506.SZ) anticipates a net loss between 890 million and 1.29 billion CNY, shifting from a profit of 68 million CNY last year due to structural supply-demand issues in the photovoltaic industry[41] - Baile Tianheng (688506.SH) projects a net loss of around 1.1 billion CNY, down from a profit of 3.708 billion CNY last year, primarily due to increased R&D expenses[42] Industry Trends - Technology-driven sectors like AI and innovative pharmaceuticals are leading growth, with companies like New Yi Sheng and Han's Chip benefiting from strong demand and technological advancements[69] - Cost control is becoming a critical competitive advantage, particularly in the energy and manufacturing sectors, as seen with companies like Datang Power (601991.SH) benefiting from lower coal prices[70] - Traditional cyclical industries such as real estate and agriculture are facing significant downward pressure, with companies like Vanke (000002.SZ) and Tianbang Foods (002124.SZ) experiencing substantial losses due to market adjustments[72]

Core Viewpoint - The article highlights the performance forecast of various A-share listed companies, indicating a significant divergence in earnings growth across different sectors, driven by technological advancements, cost control, and industry cycles [4][62]. Group 1: Companies with Strong Earnings Growth - **New Yisheng (300502.SZ)**: Expected net profit of 9.4 billion to 9.9 billion, a year-on-year increase of 231.24% to 248.86%, driven by rising demand for high-speed optical modules due to global computing power investments [6]. - **Han's Laser (688256.SH)**: Expected net profit of 1.85 billion to 2.15 billion, turning from a loss of 0.452 billion in the previous year, benefiting from the increasing demand for AI computing power [8]. - **Zhongji Xuchuang (300308.SZ)**: Expected net profit of 9.8 billion to 11.8 billion, a year-on-year increase of 89.50% to 128.17%, supported by strong investment in computing infrastructure [10]. - **Runze Technology (300442.SZ)**: Expected net profit of 5 billion to 5.3 billion, a year-on-year increase of 179.28% to 196.03%, primarily due to non-recurring gains from public REITs issuance [12]. - **CITIC Securities (601995.SH)**: Expected net profit of 8.542 billion to 10.535 billion, a year-on-year increase of 50% to 85%, driven by steady growth in core business segments [15]. Group 2: Companies with Earnings Below Expectations - **Great Wall Motors (601633.SH)**: Expected net profit of 9.912 billion, a year-on-year decrease of 21.71%, impacted by increased marketing expenses and intense competition [34]. - **GAC Group (601238.SH)**: Expected net profit of -8 billion to -9 billion, turning from a profit of 0.824 billion in the previous year, due to fierce competition and adjustments in product structure [36]. - **GCL-Poly Energy (002506.SZ)**: Expected net profit of -0.89 billion to -1.29 billion, turning from a profit of 0.068 billion, affected by structural supply-demand issues in the photovoltaic industry [38]. - **Boli Tianheng (688506.SH)**: Expected net profit of -1.1 billion, turning from a profit of 3.708 billion, due to increased R&D expenses [39]. - **Daiyue City (000031.SZ)**: Expected net profit of -2.7 billion to -2.1 billion, continuing losses from the previous year, influenced by asset impairment provisions [42]. Group 3: Industry Trends - **Technological Breakthroughs**: Industries driven by technology, such as AI and innovative pharmaceuticals, are showing strong growth, with companies like New Yisheng and Rongchang Bio leading the way [62][63]. - **Cost Control**: The energy and manufacturing sectors are experiencing a clear divide, with companies like Datang Power benefiting from lower coal prices and effective cost management [64]. - **Downward Pressure from Industry Cycles**: The real estate, agriculture, and photovoltaic sectors are under significant pressure, with companies like Vanke and Tianbang Food facing substantial earnings declines [65][66].

医药企业近日陆续披露年报预告，据东方财富Choice数据统计，截至目前，A股医药生物板块有137家 企业预告2025年亏损，其中首亏、增亏的企业数量占比一半以上；而预计去年归属于母公司的净利润亏 损最高的，达到137亿元。 药企亏损的背后，受制于多方面因素，其中产品价格下跌成为高频词。 亏损最高的超百亿 具体看这137家预告亏损的医药生物企业，涵盖了原料药、化学制剂、中药、疫苗、医药流通、体外诊 断、医疗耗材、医疗研发外包、医疗设备等细分领域，从预告归属于母公司的净利润下限指标看，亏损 最大的是智飞生物（300122.SZ），去年业绩首亏，公司预计归属于母公司的净利润亏损最高可达到 137.26亿元；紧接着是珍宝岛（603567.SH），预计去年归属于母公司的净利润亏损最高可达到11.73亿 元；之后是百利天恒（688506.SH），预计去年归属于母公司的净利润亏损最高可达到11亿元。 另外，蓝帆医疗（002382.SZ）、神州细胞（688520.SH）、润达医疗（603108.SH）、广济药业 （000952.SZ）这四家企业预计去年归属于母公司的净利润亏损最高可超过5亿元。 A股医药生物板块企业的亏损，受 ...

Core Viewpoint - The report highlights significant target price increases for several listed companies from January 26 to February 1, with notable mentions including Baili Tianheng, Zexing Pharmaceutical, and Great Wall Motors, indicating strong bullish sentiment in the market for these stocks [1][2]. Target Price Increases - Baili Tianheng (688506) has a target price increase of 375.97%, with a highest target price set at 1322.00 yuan [2]. - Zexing Pharmaceutical (688266) shows a target price increase of 88.56%, with a highest target price of 166.16 yuan [2]. - Great Wall Motors (601633) has a target price increase of 83.66%, with a highest target price of 38.00 yuan [2]. - Other companies with notable target price increases include Industrial Fulian (601138) at 73.31% and CATL (300750) at 71.71% [2][3]. Broker Recommendations - A total of 265 listed companies received broker recommendations during the period, with Qingdao Bank receiving the highest number of recommendations at 8 [3][4]. - Other companies with multiple recommendations include Xian Dao Intelligent and Wancheng Group, each receiving 5 recommendations [3][4]. Rating Adjustments - Eight companies had their ratings upgraded, including Shanghai Jahwa (600315) from "Hold" to "Buy" and ZTE Corporation (000063) from "Cautious Buy" to "Buy" [5][6]. - Two companies had their ratings downgraded, including Jincheng Shares (603396) from "Buy" to "Hold" and Huasheng Group (603018) from "Buy" to "Hold" [6]. First-Time Coverage - During the same period, 75 instances of first-time coverage were reported, with notable ratings including Shaanxi Tourism (603402) receiving a "Outperform Industry" rating and Bichu Electronics (688188) receiving a "Buy" rating [7].

1月30日晚间，百利天恒发布业绩预告称，预计2025年实现归属净利润为-11亿元左右，同比由盈转亏。 对于业绩亏损，百利天恒表示，去年为加快推进产品管线的研发进度，巩固产品管线的领先优势，早日实现产品上市以惠及患者，公司持续加大研发投 入，导致研发投入同比增幅较大。 公司还表示，去年公司与百时美施贵宝(BMS)就iza-bren的合作顺利推进，全球II/III期关键注册临床试验IZABRIGHT-Breast01里程碑达成，并收到第一笔 2.5亿美元里程碑付款。上年同期，公司收到BMS就iza-bren合作协议的8亿美元不可撤销、不可抵扣的首付款，公司相应确认相关知识产权收入。去年收 入下降主要原因为上年同期收到BMS首付款所确认的知识产权收入大于报告期内确认的里程碑收入。 截至去年末，公司共有17款创新药处于临床试验阶段(其中6款创新药处于全球临床试验)。公司正在全球范围内开展100余项创新药临床试验。核心产品 iza-bren(EGFR×HER3双抗ADC)两个适应症——用于治疗局部晚期或转移性鼻咽癌、用于治疗复发性或转移性食管鳞癌——的上市申请(NDA)已获得国家 药监局药品审评中心受理且被纳入优先审评 ...

证券代码：688506 证券简称：百利天恒 公告编号：2026-009 二、上年同期业绩情况和财务状况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年度实现营业收入为250,000.00万元左右，与上年同期相比将减少 332,271.78万元左右，同比减少57.06%左右。 2、经财务部门初步测算，预计2025年度实现归属于母公司所有者的净利润为-110,000.00万元左右，与 上年同期相比将减少480,750.46万元左右，同比减少129.67%左右。 3、经财务部门初步测算，预计2025年度实现归属于母公司所有者扣除非经常性损益后的净利润 为-120,000.00万元左右，与上年同期相比将减少483,553.75万元左右，同比减少133.01%左右。 （三）本次业绩预告未经注册会计师审计。 公司不存在影响本次业绩预告内容准确性的重大不确定因素，本次业绩预告是公司财务部门基 ...

2025年三季度末，百利天恒经营活动产生的现金流量净额为-18.92亿元。截至2026年1月30日，百利天恒尚未宣布重启港股上市计划。 2024年，百利天恒实现营业收入58.23亿元，净利润为37.08亿元，扣非净利润为36.36亿元。 百利天恒称，2025年业绩变化的主要原因如下：一方面，为加快推进产品管线的研发进度，巩固产品管线的领先优势，早日实现产品上市以惠及患者，公 司在2025年持续加大研发投入，研发投入同比增幅较大。 另一方面，2025年公司与百时美施贵宝（BMS）就iza-bren的合作顺利推进，全球II/III期关键注册临床试验IZABRIGHT-Breast01里程碑达成，并收到第一 笔2.5亿美元里程碑付款。上年同期，公司收到BMS就iza-bren合作协议的8亿美元不可撤销、不可抵扣的首付款，公司相应确认相关知识产权收入。2025 年收入下降主要原因为上年同期收到BMS首付款所确认的知识产权收入大于报告期内确认的里程碑收入。 2025年10月21日，百利天恒通过港交所上市委员会聆讯；2025年11月12日，百利天恒公告延迟港股上市计划。 百利天恒在2025年11月12日发布的公告中称，原 ...

评级：中性(维持) 曹泽运(证券分析师) 李畅(证券分析师) S0350525110001 S0350524010004 caozy@ghzq.com.cn lic05@ghzq.com.cn 证券研究报告 2026年01月30日 医药生物 生物医药深度报告：国产ADC药物即将迎来高光时刻 ——ADC子行业专题研究 最近一年走势 相关报告 《医药生物行业动态研究：中国独立医学实验室行业的先行者（中性）*医药生 物*曹泽运，林羽茜》——2026-01-27 《医药生物行业动态研究：AI药研或引产业革命，JPM大会再推行业新峰（中 性）*医药生物*曹泽运，林羽茜》——2026-01-20 相对沪深300表现 | 表现 | 1M | 3M | 12M | | --- | --- | --- | --- | | 医药生物 | 2.0% | -2.7% | 21.1% | | 沪深300 | 2.1% | 1.3% | 24.5% | 请务必阅读报告附注中的风险提示和免责声明 2 -9% 0% 9% 19% 28% 37% 2025/02/05 2025/05/06 2025/08/04 2025/11/02 医药生物 ...

百利天恒表示，报告期内，为加快推进产品管线的研发进度，巩固产品管线的领先优势，早日实现产品 上市以惠及患者，公司持续加大研发投入，导致研发投入同比增幅较大。 北京商报讯（记者 丁宁）1月30日晚间，百利天恒（688506）发布2025年业绩预告显示，经财务部门初 步测算，预计2025年实现归属净利润为-11亿元左右，同比减少129.67%左右。 同时，报告期内，公司与百时美施贵宝（BMS）就iza-bren 的合作顺利推进，全球II/III期关键注册临床 试验IZABRIGHT-Breast01里程碑达成，并收到第一笔2.5亿美元里程碑付款。上年同期，公司收到BMS 就iza-bren合作协议的8亿美元不可撤销、不可抵扣的首付款，公司相应确认相关知识产权收入。报告期 内收入下降主要原因为上年同期收到BMS首付款所确认的知识产权收入大于报告期内确认的里程碑收 入。 ...